Division of Bioinformation and Therapeutic Systems, National Defense Medical College Research Institute, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Division of Bioinformation and Therapeutic Systems, National Defense Medical College Research Institute, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Photodiagnosis Photodyn Ther. 2023 Dec;44:103861. doi: 10.1016/j.pdpdt.2023.103861. Epub 2023 Oct 24.
We previously developed a site-specific transvascular drug delivery system (DDS) based on photomechanical waves (PMWs) or laser-induced stress/shock waves (LISWs). In this study, we investigated the validity of this method to deliver a clinical photosensitizer, talaporfin sodium (TS), to subcutaneous tumors in mice and to enhance the efficacy of photodynamic therapy (PDT).
TS solution (2.5 mg/kg) was intravenously injected into mice. Immediately thereafter, PMWs were applied to the tumor by irradiating a laser target with a Q-switched ruby laser pulse (0.8 J/cm). Five hours after TS administration, some tumors were excised to evaluate the depth distribution of the delivered TS under a fluorescence microscope. Other tumors were subjected to PDT by irradiating the tissues with a 665 nm continuous-wave laser diode (75 mW/cm, 667 s) at this timepoint. The effects of PDT were evaluated on the basis of the two primary therapeutic mechanisms of TS-mediated PDT: i) damage to tumor cells and ii) damage to endothelial cells of tumor vessels, i.e., the vascular shutdown effect on tumors.
PMW application significantly increased the accumulation of TS in the tumor parenchyma but not in the tumor vessel walls; the endothelial cell junctions of tumor vessels should be the route of TS delivery enhanced by PMWs. Thus, as a result of PMW application followed by PDT, while the vascular shutdown effect on the tumors was not enhanced, direct damage to the tumor cells was increased, resulting in significant tumor growth retardation without body weight loss for 7 days after treatment.
我们先前开发了一种基于光机械波(PMWs)或激光诱导的应力/冲击波(LISWs)的靶向血管内药物输送系统(DDS)。在这项研究中,我们研究了这种方法将临床光敏剂替拉扎明钠(TS)输送到小鼠皮下肿瘤并增强光动力疗法(PDT)效果的有效性。
将 TS 溶液(2.5mg/kg)静脉注射入小鼠体内。此后,立即通过用调 Q 红宝石激光脉冲(0.8J/cm)照射激光靶标来向肿瘤施加 PMWs。TS 给药后 5 小时,切除一些肿瘤以在荧光显微镜下评估输送的 TS 的深度分布。此时,通过用 665nm 连续波激光二极管(75mW/cm,667s)照射组织对其他肿瘤进行 PDT。基于 TS 介导的 PDT 的两种主要治疗机制:i)肿瘤细胞损伤和 ii)肿瘤血管内皮细胞损伤,即对肿瘤的血管关闭效应,评估 PDT 的效果。
PMW 应用显著增加了 TS 在肿瘤实质中的积累,但不在肿瘤血管壁中;PMWs 增强的 TS 输送途径应该是肿瘤血管的内皮细胞连接。因此,由于 PMW 应用后进行 PDT,尽管对肿瘤的血管关闭效应没有增强,但对肿瘤细胞的直接损伤增加,导致治疗后 7 天内肿瘤生长明显延迟而无体重减轻。